1378888-43-7Relevant articles and documents
Siponimod intermediate and preparation method thereof
-
Paragraph 0100-0105, (2021/10/27)
The invention relates to a siponimod intermediate and a preparation method thereof, and belongs to the field of medicinal chemistry. According to the preparation method, by taking 2-ethylaniline as a starting material, 1-(3-ethyl-4-hydroxymethyl) acetophenone is obtained through multi-step reaction. The method has the advantages of high yield, simple and easily available raw materials, low cost and controllable reaction conditions and temperature, and is suitable for industrial large-scale production.
Method for preparing 3-ethyl-4-methylol acetophenone
-
Paragraph 0014-0015; 0017; 0019, (2019/03/28)
The invention discloses a method for preparing 3-ethyl-4-methylol acetophenone. The method includes steps of S1, carrying out coupling reaction on 4-methylol-3-bromoacetophenone and trimethylsilylacetylene or ethynyltriisopropylsilane to generate 3-trimethyl silicon acetenyl-4-methylol acetophenone; S2, hydrolyzing the 3-trimethyl silicon acetenyl-4-methylol acetophenone under alkaline conditionsto generate 3-acetenyl-4-methylol acetophenone; S3, carrying out reduction on the 3-acetenyl-4-methylol acetophenone under the conditions of hydrogen, palladium and carbon to obtain the 3-ethyl-4-methylol acetophenone. The method has the advantages that the yield of the 3-ethyl-4-methylol acetophenone can be greatly increased, the highest yield of the 3-ethyl-4-methylol acetophenone can reach 55%at least, the method includes simple reaction steps and is easy to control, and reaction procedures are mild.
Discovery of BAF312 (Siponimod), a potent and selective S1P receptor modulator
Pan, Shifeng,Gray, Nathanael S.,Gao, Wenqi,Mi, Yuan,Fan, Yi,Wang, Xing,Tuntland, Tove,Che, Jianwei,Lefebvre, Sophie,Chen, Yu,Chu, Alan,Hinterding, Klaus,Gardin, Anne,End, Peter,Heining, Peter,Bruns, Christian,Cooke, Nigel G.,Nuesslein-Hildesheim, Barbara
supporting information, p. 333 - 337 (2013/04/24)
A novel series of alkoxyimino derivatives as S1P1 agonists were discovered through de novo design using FTY720 as the chemical starting point. Extensive structure-activity relationship studies led to the discovery of (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl) -2-ethylbenzyl)azetidine-3-carboxylic acid (32, BAF312, Siponimod), which has recently completed phase 2 clinical trials in patients with relapsing-remitting multiple sclerosis.